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Abstract
Background: The optimal colloid solution for the treatment of ovarian hyperstimulation
syndrome (OHSS) remains to be established.
Objective: We aimed to compare artificial colloids (AC) with human albumin (HA) for
the treatment of OHSS.
Materials and Methods: In this retrospective cohort study, data for OHSS participants
were collected from a national inpatient database in Japan. The participants received
intravenous fluid management with AC (n = 156) or HA (n = 127). We compared the two
groups in terms of the length of stay, development of post-treatment complications,
and termination surgery.
Results: In multivariable linear regression analyses for log-transformed length of stay
with reference to the OHSS participants receiving AC, the regression coefficient (95%
confidence interval) in participants receiving HA was 0.03 (-0.04-0.09, p = 0.42).
Thromboembolism occurred in two participants in the HA group and three participants
in the AC group. Two participants in the HA group suffered renal failure during
hospitalization. No participants underwent termination surgery in the two groups.
Conclusions: The present results showed comparable efficacy between AC and HA
for the treatment of OHSS. There were no significant differences in post-treatment
complications between the two groups.
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1. Introduction
Ovarian hyperstimulation syndrome (OHSS) is an
iatrogenic and potentially life-threatening compli-
cation that affects 1–14% of all assisted reproduc-
tive therapy cycles (1). Exogenous gonadotrophin
administration for the induction of ovulation can
lead to ovary enlargement and fluid shift from
intravascular spaces to third spaces because of
an increased capillary permeability (2). Mild OHSS
is self-limiting and gradually resolves by the time
of the next menstrual period in patients who
do not conceive. Patients who develop severe
OHSS experience dyspnea, acute renal failure, and
thromboembolism (3).
In patients at risk, the prevention of OHSS is
the best strategy. Conservative treatments aim to
relieve symptoms and prevent complications of
OHSS. Patients with severe OHSS need to be
admitted to hospital and receive carefulmonitoring,
frequent examination, thromboprophylaxis, surgi-
cal intervention, and intravenous fluid manage-
ment (4).
The crystalloid solution should be administered
immediately to correct intravascular volume and
provide end-organ perfusion. However, excessive
administration can contribute to worsening ascites
or pleural effusion. The colloid solution is a feasible
option for diuresis. The optimal colloid solution for
the treatment of OHSS remains to be established. A
few studies have compared the outcomes between
artificial colloids (AC; hydroxyethyl starch [HES]
and/or dextran) and human albumin (HA) in OHSS
patients, with inconsistent results (5, 6). However,
these studies were limited by their small sample
sizes.
In the present study, we compared AC with HA
in terms of hospital stay and the development of
post-treatment complications, using a nationwide
inpatient database in Japan.
2. Materials and Methods
2.1. Data source
The present retrospective cohort study utilized
the Diagnosis Procedure Combination database,
comprising administrative claims data and dis-
charge information for acute-care inpatients in
Japan. The database contains the following infor-
mation: age and conception; main diagnoses
on admission, comorbidities on admission, and
complications developed during hospitalization
encoded with International Classification of Dis-
eases and Related Health Problems Tenth Revi-
sion codes; admission history for OHSS; inter-
ventions, including paracentesis, auto transfusion
of concentrated ultra-filtered ascetic fluid, and
oxygen administration; solutions, blood products,
and drugs administered; and the dates of admis-
sion, discharge, and medical interventions. The
database does not contain any laboratory data or
imaging examination findings.
2.2. Sample selection
We collected data from the women who were
admitted to the hospital with a diagnosis of OHSS
from July 2010 to March 2016. We included partic-
ipants who were administered crystalloid solutions
followed by colloid solutions within two days of
admission. We excluded women who: (i) were
diagnosed with adnexal torsion, ovarian rupture,
thromboembolism, or cerebral infarction on admis-
sion; (ii) received any surgical procedure, such as
exploratory laparotomy or adnexectomy, within two
days of admission; and (iii) received both AC and
HA. We divided the eligible participants into an AC
group and an HA group based on their treatment.
AC were defined as HES, dextran, and mannitol.
HA included 5% or 25% products.
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2.3. Participants’ background charac-
teristics and outcomes
Data for the following background characteris-
tics were collected: age; conception; OHSS his-
tory; comorbidity of polycystic ovary syndrome
(PCOS); paracentesis; auto transfusion of concen-
trated ultra-filtered ascetic fluid; dopamine com-
bined therapy; and total dose of crystalloid solution
within two days of admission. Participants with
respiratory comorbidities and those requiring res-
piratory support within two days of admission were
classified as severe OHSS according to the OHSS
classification (7, 8). Respiratory comorbidities were
defined as pleural effusion, pulmonary edema, and
acute respiratory distress syndrome. Respiratory
support was defined as oxygen administration,
pleuracentesis, and mechanical ventilation. Partic-
ipants who received treatments for ascites and/or
pleural effusion were divided into a paracentesis/-
pleura centesis group and an autotransfusion of the
concentrated ultra-filtered ascetic fluid group.
The primary outcome was the length of stay
(LOS). The secondary outcomes were the devel-
opment of post-treatment complications and termi-
nation surgery. The post-treatment complications
included adnexal torsion, ovarian rupture, throm-
boembolism, cerebral infarction, and renal failure
after admission.
2.4. Ethical consideration
The study was approved by the Institutional
Review Board and Ethics Committee of The Univer-
sity of Tokyo (3501). The requirement for informed
consent was waived because of the anonymous
nature of the data.
2.5. Statistical analyses
In comparisons of baseline characteristics and
outcomes between the groups, categorical data
were compared by the Chi-squared test or Fisher’s
exact test, and continuous data were compared
using the Mann-Whitney U-test or Student’s t-tests,
as appropriate. In multivariable analyses, age was
categorized into≤ 34 and> 35 yr, and LOSwas log-
transformed because of its non-normal distribution.
The present study was a retrospective study, and
the treatment allocation was not random. Decisions
on treatment options were made by individual
physicians taking the background characteristics
of their participants into account. Therefore, we
used multivariable regression analyses for log-
transformed LOS with adjustment for patient back-
ground characteristics, while also adjusting for
within-hospital clustering using generalized esti-
mating equations.
All statistical analyses were conducted using
SPSS Statistics version 22.0 (Statistical Package for
the Social Sciences, IBM Corp., Armonk, NY, USA).
The threshold for significance was p < 0.05 in all
statistical analyses.
3. Results
We identified 2,161 OHSS cases in the Diagnosis
Procedure Combination database from July 2010
to March 2016. Among these women, 283 were
eligible for the present study (AC group, n = 156;
HA group, n = 127). The distributions of the partici-
pants’ characteristics are shown in Table I and the
participants’ outcomes are shown in Table II.
As shown in Table I, there were significantly
higher proportions of severe OHSS, dopamine
combined therapy, and paracentesis/pleura cente-
sis in the HA group compared with the AC group.
The number of younger age (≤ 34 yr) women
were 103 and 88, in the AC group and the HA
group, respectively. The total amount of crystalloid
solution in the HA group was significantly larger
than that in the AC group.
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As indicated in Table II, LOS was shorter in
the AC group compared with the HA group (9
days vs 11 days, p < 0.001). Adnexal torsion,
ovarian rupture, and cerebral infarction did not
occur in either group. Pulmonary embolism
was not detected in the two participants with
thromboembolism in the HA group but was
detected in one of the three participants with
thromboembolism in the AC group. The two
participants in the HA group suffered renal
failure during hospitalization. There were
no significant differences in post-treatment
complications between the two groups. No
participants underwent termination surgery in
either group.
The results of the multivariable linear regres-
sion analyses for the primary outcome are shown
in Table III. Older age (> 35 yr), conception,
treatments for ascites and/or pleural effusion, and
dopamine combined therapy were associated with
longer LOS. However, with reference to the partic-
ipants in the AC group, the regression coefficient
(95% confidence interval) in the HA group was 0.03
(-0.04-0.09).
Table I. Patient background characteristics
Variables Artificial colloid (n = 156) Human albumin (n = 127) P-value
Age (yr)* 32.7 ± 4.4 32.0 ± 4.1 0.36𝑎
Severe OHSS**# 9 (5.8) 34 (27) < 0.001𝑏
OHSS history** 10 (6.4) 10 (7.9) 0.65𝑏
Comorbidity of PCOS** 5 (3.2) 4 (3.1) 1.000𝑐
Conception** 26 (17) 36 (28) 0.069𝑏
Type of treatment for ascites and/or pleural effusion**
None 124 (80) 99 (78) 0.753𝑏
Paracentesis/ pleura centesis 5 (3.2) 11 (8.7) 0.048𝑏
Auto transfusion of concentrated ultra-filtered
ascetic fluid
27 (17) 17 (13) 0.365𝑏
Dopamine combined therapy** 82 (53) 86 (68) 0.011𝑏
Total dose of crystalloid within 2 days (/100 ml)*** 20 (15-25) 25 (15-31.6) < 0.001𝑎
*Data presented as mean ± SD; **data presented as n (%); ***data presented as median (IQR)
a = Mann-Whitney U-test; b = Chi-squared test; c = Fisher’s exact test
#Participants with respiratory comorbidities and those requiring respiratory support within two days of admission were
classified as severe OHSS
OHSS: Ovarian hyperstimulation syndrome PCOS: Polycystic ovarian syndrome IQR: Interquartile range
Table II. Participants’ outcomes
Artificial colloid (n = 156) Human albumin (n = 127) P-value
Post-treatment complications*
Adnexal torsion 0 (0.00) 0 (0.00)
Ovarian rupture 0 (0.00) 0 (0.00)
Cerebral infarction 0 (0.00) 0 (0.00)
Thromboembolism 2 (1.3) 3 (2.4) 0.67𝑎
Pulmonary embolism 0 (0.00) 1 (0.8) 0.45𝑎
Renal failure 0 (0.00) 2 (1.6) 0.20𝑎
Termination surgery* 0 (0.00) 0 (0.00)
Hospital stay** 9.0 (6-13) 11.0 (8-17) < 0.001𝑏
*Data presented as mean ± SD; **data presented as median (IQR); IQR: Interquartile range
a = Fisher’s exact test; b = Mann-Whitney U-test
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Table III. Multivariable linear regression analyses with general estimation equations for log-transformed length of stay
Variable Regression coefficient (95% CI) P-value
Age (years)
≤ 34 Reference
> 35 0.062 (0.009-0.12) 0.021
Severe −0.008 (−0.12-0.11) 0.89
OHSS history −0.001 (−0.003-0.06) 0.97
Comorbidity of PCOS −0.086 (−0.024-0.068) 0.27
Conception 0.27 (0.19-0.35) < 0.001
Treatments for ascites and/or pleural effusion
None Reference




Dopamine combined therapy 0.14 (0.086-0.19) < 0.001





Human albumin 1.3 (−0.81-3.34) 0.23
CI: Confidence interval; OHSS: Ovarian hyperstimulation syndrome; PCOS: Polycystic ovarian syndrome
Older age (> 35 yr), conception, treatments for ascites and/or pleural effusion, and dopamine combined therapy were
associated with longer LOS. However, with reference to patients in the artificial colloid group, the regression coefficient (95%
confidence interval) in the human albumin group was 0.03 (−0.04-0.09)
4. Discussion
In the present large retrospective cohort study
using a nationwide inpatient database in Japan,
we found comparable efficacy between AC and
HA for intravenous fluid management in OHSS par-
ticipants, after adjustment for confounding factors.
In addition, most of the OHSS participants admit-
ted without critical comorbidities had uneventful
courseswithout the development of post-treatment
complications.
A small-sized retrospective study suggested
that HES may be superior to HA in colloid solu-
tions for reducing LOS and paracentesis, and
increasing urine output (5). A non-randomized
clinical trial suggested that dextran had greater
efficacy for the treatment of hemoconcentration
caused by OHSS than HA, but did not assess
complications and LOS (6). Therefore, the opti-
mal colloid solutions for the treatment of OHSS
remain to be established, and the present study
showed comparable efficacy between AC and
HA. This finding is pathophysiologically plausible
because these colloid solutions have no effect
on the hypothalamic-pituitary-ovarian system, and
are biochemical substances that increase capillary
permeability and vascular endothelial cells. HA
solution is a finite resource and should be sup-
plied optimally to patients with severe diseases,
such as liver cirrhosis, nephrotic syndrome, and
hemorrhagic shock. Infections remain of concern,
especially in reproductive-age women. In particu-
lar, human parvovirus B19 infection by the adminis-
tration of blood products can lead to miscarriage,
fetal edema, and anemia (9). In addition, HA is
10-fold as expensive as AC (approximately $45
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per 5% albumin 250 ml vs $4.5 per AC 250 ml)
(10).
AC has several advantages in terms of being
biohazard-free, cost-effective, and safe. It is con-
ceivable that AC may have adverse effects on
renal function. Although a randomized clinical
trial showed no evidence for a colloid-related
increase in the risk of renal replacement therapy
among hypovolemic participants in the intensive
care unit (11), the importance of compliance with
the dose recommended by regulatory agencies
was mentioned. We considered that the results
of the previous study could be generalizable
to the OHSS participants. However, there were
several concerns about the aggressive use of
AC. First, HES and dextran can interact with the
blood coagulation system. In one case report
involving OHSS, this interaction led to delayed
persistent pleural effusion and significant blood
coagulation alteration despite hormonal resolution
(12). Meanwhile, this interaction can potentially be
used for thromboprophylaxis (13). Second, there
may be effects on fetuses. Two studies showed
that HES did not cross the placental barrier in
rats and sheep (14, 15). Although these findings
may also apply to humans, further studies are
required.
Late-onset OHSS, caused by conception, is cor-
related with endogenous gonadotrophin produced
by an embryo or administration of gonadotrophin
for luteal phase support (16). The present results
are consistent with the fact that endogenous
gonadotrophin can lead to worsening and prolon-
gation of OHSS.
Longer LOS was significantly associated with
treatments for ascites and/or pleural effusion and
dopamine combined therapy but was not asso-
ciated with severe OHSS. Our classification of
severe OHSS depended on respiratory comorbidi-
ties and the requirement for respiratory support,
and thus we could havemisclassified severe OHSS
participants who received treatments for ascites
and/or pleural effusion and dopamine combined
therapy.
Several studies showed that younger age, OHSS
history, and comorbidity of PCOS were risk factors
for developing OHSS (8, 16-18). In the present
study, these factors were not associated with LOS.
A possible explanation for these findings is that
physiciansmay have tended to admit such high-risk
participants for even mild OHSS.
We did not assess allergic reactions because
recorded diagnoses of allergic reactions may not
be well validated due to the retrospective nature
of the data. A previous systematic review showed
little or no difference in allergic reactions for the
use of AC vs HA (19).
4.1. Limitations
Several limitations should be addressed. First,
data on precise body mass index were not avail-
able, because OHSS participants may have been
overweight because of ascites. The database did
not include data on artificial reproductive tech-
nologies including ovulation induction, presence or
absence of luteal phase support, single or multiple
embryo transfers, and ovarian reserve markers.
Although the associations of these components
with OHSS development were reported (16, 20),
the associations with OHSS prolongation have
not been reported. Second, the study was not
a randomized clinical trial, and possible unmea-
sured confounders may have affected the results.
Third, because the Diagnosis Procedure Combi-
nation database was not created for research
purposes, the findings should be interpreted care-
fully, because recorded diagnoses in retrospective
databases are generally less well validated than
those in planned prospective studies. However,
a previous validation study of the Diagnosis
Procedure Combination database showed high
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specificity of diagnoses and procedure records
(21). Finally, we could not follow the maternal and
neonatal outcomes, especially miscarriages that
did not require interventions and live birth rates.
5. Conclusion
In conclusion, our results showed comparable
efficacy between AC and HA for intravenous
fluid management in OHSS patients. We suggest
that the use of AC was optimal in terms of
their biohazard-free nature, cost-effectiveness, and
safety.
Acknowledgements
This work was supported by the grants from
the Ministry of Health, Labour and Welfare,
Japan [H29-Policy-Designated-009 and H29-ICT-
General-004]; the Ministry of Education, Culture,
Sports, Science and Technology, Japan [17H04141];
and the Japan Agency for Medical Research and
Development (AMED).
Conflict of Interest
No conflicts of interest are disclosed.
References
[1] Garcia-Velasco JA, Pellicer A. New concepts in the under-
standing of the ovarian hyperstimulation syndrome. Curr
Opin Obstet Gynecol 2003; 15: 251–256.
[2] Kwik M, Maxwell E. Pathophysiology, treatment and pre-
vention of ovarian hyperstimulation syndrome. Curr Opin
Obstet Gynecol 2016; 28: 236–241.
[3] Borase H, Mathur R. Ovarian hyperstimulation syndrome:
clinical features, prevention and management. Obstet
Gynaecol Reprod Med 2012; 22: 186–190.
[4] ChenCD, Chen SU, Yang YS. Prevention andmanagement
of ovarian hyperstimulation syndrome. Best Pract Res Clin
Obstet Gynaecol 2012; 26: 817–827.
[5] Abramov Y, FatumM, Abrahamov D, Schenker JG. Hydrox-
yethyl starch versus human albumin for the treatment of
severe ovarian hyperstimulation syndrome: a preliminary
report. Fertil Steril 2001; 75: 1228–1230.
[6] Endo T, Kitajima Y, Hayashi T, Fujii M, Hata H, Azumaguchi
A. Low-molecular-weight dextran infusion is more effective
for the treatment of hemoconcentration due to severe
ovarian hyperstimulation syndrome than human albumin
infusion. Fertil Steril 2004; 82: 1449–1451.
[7] Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi
E. Ovarian hyperstimulation syndrome: an update review.
Obstet Gynecol Surv 1989; 44: 430–440.
[8] Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation
syndrome in novel reproductive technologies: prevention
and treatment. Fertil Steril 1992; 58: 249–261.
[9] Crane J, Mundle W, Boucoiran I. Parvovirus B19 infection
in pregnancy. J Obstet Gynaecol Can 2014; 36: 1107–1116.
[10] Ministry of Health. [Labour and Welfare, List of drug
price]. Available at: https://www.mhlw.go.jp/topics/2019/
08/dl/tp20191001-01_02.pdf. Accessed September 16,
2019. (In Japanese)
[11] Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere
AD, et al. Effects of fluid resuscitation with colloids vs
crystalloids on mortality in critically ill patients presenting
with hypovolemic shock: the CRISTAL randomized trial.
JAMA 2013; 310: 1809–1817.
[12] Kissler S, Neidhardt B, Siebzehnrubl E, Schmitt H,
Tschaikowsky K, Wildt L. The detrimental role of colloidal
volume substitutes in severe ovarian hyperstimulation
syndrome: a case report. Eur JObstet Gynecol Reprod Biol
2001; 99: 131–134.
[13] Jin S, Yu G, Hou R, Shen B, Jiang H. Effect of hemodilution
in vitro with hydroxyethyl starch on hemostasis. Med Sci
Monit 2017; 23: 2189–2197.
[14] Marcus MA, Vertommen JD, Van Aken H. Hydroxyethyl
starch versus lactated Ringer’s solution in the chronic
maternal-fetal sheep preparation: a pharmacodynamic
and pharmacokinetic study. Anesth Analg 1995; 80: 949–
954.
[15] Stander S, Bone HG, Machens HG, Aberle T, Burchard
W, Prien T, et al. Hydroxyethyl starch does not cross the
blood-brain or the placental barrier but the perineurium
of peripheral nerves in infused animals. Cell Tissue Res
2002; 310: 279–287.
[16] Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Dis-
tinction between early and late ovarian hyperstimulation
syndrome. Fertil Steril 2000; 73: 901–907.
[17] Aramwit P, Pruksananonda K, Kasettratat N, Jammeechai
K. Risk factors for ovarian hyperstimulation syndrome in
Thai patients using gonadotropins for in vitro fertilization.
Am J Health Syst Pharm 2008; 65: 1148–1153.
[18] Swanton A, Lighten A, Granne I, McVeigh E, Lavery S, Trew
G, et al. Do women with ovaries of polycystic morphology
without any other features of PCOS benefit from short-
term metformin co-treatment during IVF? A double-blind,
placebo-controlled, randomized trial. Hum Reprod 2011;
26: 2178–2184.
[19] Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson
P, Smith AF, et al. Colloids versus crystalloids for fluid
resuscitation in critically ill people. Cochrane Database
https://doi.org/10.18502/ijrm.v17i10.5287 Page 715
International Journal of Reproductive BioMedicine Minami et al.
Syst Rev 2018; 8: doi: 10.1002/14651858.CD000567.
[20] Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN,
et al. Serum anti-Mullerian hormone and estradiol levels
as predictors of ovarian hyperstimulation syndrome in
assisted reproduction technology cycles. Hum Reprod
2008; 23: 160–167.
[21] Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K,
Yasunaga H. Validity of diagnoses, procedures, and labo-
ratory data in Japanese administrative data. J Epidemiol
2017; 27: 476–482.
Page 716 https://doi.org/10.18502/ijrm.v17i10.5287
